NASDAQ: KLRS
Kalaris Therapeutics Inc
Healthcare · Biotechnology
After hours: $4.03(0%) · as of 4:10 PM ET
Market Cap
$87.96M
52w High
$11.88
52w Low
$3.03
P/E
-2.00
Volume
52.61K
Outstanding Shares
21.83M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 13.2% over the last year. Free cash flow declined 71.21% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Valuation
Stock splits
Every 23 shares became 1
Profitability & growth
Analyst consensus
1
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 11, 2026
Q4 FY26 · EPS est -$0.52 · Revenue est —
View